tiprankstipranks
Trending News
More News >
Vikas Lifecare Limited (IN:VIKASLIFE)
:VIKASLIFE
India Market
Advertisement

Vikas Lifecare Limited (VIKASLIFE) AI Stock Analysis

Compare
1 Followers

Top Page

IN:VIKASLIFE

Vikas Lifecare Limited

(VIKASLIFE)

Rating:47Neutral
Price Target:
₹2.50
▲(10.62% Upside)
Vikas Lifecare Limited's stock score is low, driven by challenging financial performance, weak technical indicators, and unattractive valuation metrics. The company's operational and cash flow inefficiencies pose significant risks, overshadowing its strong equity structure.

Vikas Lifecare Limited (VIKASLIFE) vs. iShares MSCI India ETF (INDA)

Vikas Lifecare Limited Business Overview & Revenue Model

Company DescriptionVikas Lifecare Limited (VIKASLIFE) is an Indian company primarily engaged in the business of recycling plastic waste and trading polymers and other related chemicals. The company operates in sectors including polymer raw materials, recycled materials, and specialty additives. It offers a wide range of products used in various industrial applications, contributing to sustainability and circular economy initiatives.
How the Company Makes MoneyVikas Lifecare Limited generates revenue through multiple streams, primarily focusing on the trading and recycling of polymers and chemicals. The company's revenue model includes sourcing and supplying virgin and recycled polymers to various industries, including packaging, automotive, and construction. Additionally, it earns income from the sale of specialty additives that enhance the properties of polymers. Strategic partnerships with suppliers and customers help Vikas Lifecare optimize its supply chain and distribution network, enhancing its market presence and profitability. The company's focus on sustainability and recycling initiatives also positions it to capitalize on the growing demand for environmentally friendly materials.

Vikas Lifecare Limited Financial Statement Overview

Summary
Vikas Lifecare Limited is facing financial challenges with declining profitability, increased debt, and negative cash flows. Despite maintaining a strong equity base, significant improvement in operational performance is required to enhance financial health.
Income Statement
45
Neutral
Vikas Lifecare Limited has shown volatile revenue growth with a notable decline in profitability. The gross profit margin is low, indicating cost pressures, and the net profit margin has deteriorated into negative territory, reflecting operational challenges. The EBIT and EBITDA margins have also weakened, contributing to financial instability.
Balance Sheet
60
Neutral
The balance sheet demonstrates a moderate debt-to-equity ratio, suggesting a balanced approach to leveraging, though the debt has increased significantly over the year. The return on equity is negative due to net losses, but the equity ratio remains strong, indicating solid capital structure despite profitability challenges.
Cash Flow
50
Neutral
Cash flow analysis reveals negative free cash flow growth and poor operating cash flow, indicating liquidity challenges. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies. The company needs to improve cash generation to support its operations.
BreakdownTTMDec 2025Dec 2023Dec 2022Dec 2022Dec 2021
Income Statement
Total Revenue4.76B4.80B4.46B3.01B4.76B749.95M
Gross Profit124.01M38.79M262.04M101.59M243.20M112.35M
EBITDA25.49M43.56M240.93M427.24M-160.98M43.39M
Net Income-90.44M-106.14M140.29M286.99M-152.99M-35.02M
Balance Sheet
Total Assets0.007.29B5.55B3.21B4.55B1.49B
Cash, Cash Equivalents and Short-Term Investments20.80M431.74M159.36M77.05M114.00M1.88M
Total Debt0.00767.00M344.90M230.77M304.07M417.57M
Total Liabilities-5.45B1.96B762.67M1.21B1.21B822.82M
Stockholders Equity5.45B5.32B4.77B1.99B3.31B666.70M
Cash Flow
Free Cash Flow0.00-2.36B-577.20M-281.03M-1.28B-91.52M
Operating Cash Flow0.00-2.24B-417.48M-148.84M-1.10B-76.82M
Investing Cash Flow0.001.03B-906.01M-385.14M-366.38M119.21M
Financing Cash Flow0.001.12B1.37B590.87M1.51B-42.69M

Vikas Lifecare Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.26
Price Trends
50DMA
2.41
Negative
100DMA
2.52
Negative
200DMA
3.10
Negative
Market Momentum
MACD
-0.04
Negative
RSI
42.33
Neutral
STOCH
45.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIKASLIFE, the sentiment is Negative. The current price of 2.26 is above the 20-day moving average (MA) of 2.25, below the 50-day MA of 2.41, and below the 200-day MA of 3.10, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 42.33 is Neutral, neither overbought nor oversold. The STOCH value of 45.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIKASLIFE.

Vikas Lifecare Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
₹4.59B72.87
0.62%-9.14%-91.11%
58
Neutral
₹3.54B47.16
19.40%1286.88%
54
Neutral
₹4.71B47.02
0.29%-9.90%33.18%
54
Neutral
₹3.65B38.50
-3.36%-47.58%
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
47
Neutral
₹4.22B
9.42%-13120.00%
43
Neutral
₹3.29B30.02
-3.41%-3028.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:VIKASLIFE
Vikas Lifecare Limited
2.26
-2.55
-53.01%
IN:ALBERTDAVD
Albert David Ltd
803.65
-732.69
-47.69%
IN:LYKALABS
Lyka Labs Limited
99.22
-56.78
-36.40%
IN:MEDICAMEQ
Medicamen Biotech Limited
351.15
-77.37
-18.06%
IN:NECLIFE
Nectar Lifesciences Ltd.
14.66
-37.03
-71.64%
IN:ZIMLAB
Zim Laboratories Ltd.
74.20
-45.50
-38.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025